LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 3 of total 3

Search options

  1. Article ; Online: Wastewater from healthcare centers in Burkina Faso is a source of ESBL, AmpC-β-lactamase and carbapenemase-producing Escherichia coli and Klebsiella pneumoniae.

    Garba, Zakaria / Bonkoungou, Isidore O J / Millogo, Nadège O / Natama, H Magloire / Vokouma, Pingdwendé A P / Bonko, Massa Dit A / Karama, Ibrahima / Tiendrebeogo, Lagmêyesgo A W / Haukka, Kaisa / Tinto, Halidou / Sangaré, Lassana / Barro, Nicolas

    BMC microbiology

    2023  Volume 23, Issue 1, Page(s) 351

    Abstract: Background: Extended-spectrum β-lactamase (ESBL), plasmid-mediated AmpC-β-lactamase and carbapenemase-producing Escherichia coli and Klebsiella pneumoniae have spread into the environment worldwide posing a potential public health threat. However, the ... ...

    Abstract Background: Extended-spectrum β-lactamase (ESBL), plasmid-mediated AmpC-β-lactamase and carbapenemase-producing Escherichia coli and Klebsiella pneumoniae have spread into the environment worldwide posing a potential public health threat. However, the prevalence data for low- and middle-income countries are still scarce. The aim of this study was to evaluate the presence of ESBL, AmpC-β-lactamase and carbapenemase-producing and multidrug-resistant E. coli and K. pneumoniae in wastewaters from healthcare centers in Burkina Faso.
    Results: Eighty-four (84) wastewater samples were collected from five healthcare centers and plated on selective ESBL ChromAgar. E. coli and Klebsiella pneumoniae isolates were identified using API20E. ESBL-producing bacteria were detected in 97.6% of the samples and their average concentration per hospital ranged from 1.10 × 10
    Conclusions: This study showed that wastewater from healthcare centers constitutes a reservoir of multidrug-resistant bacteria in Burkina Faso, including carbapenemase producers. Untreated healthcare wastewater entering the environment exposes people and animals to infections caused by these multi-resistant bacteria, which are difficult to treat, especially in the resource-poor settings.
    MeSH term(s) Humans ; Animals ; Escherichia coli ; Klebsiella pneumoniae ; Wastewater ; Burkina Faso ; Microbial Sensitivity Tests ; beta-Lactamases ; Bacterial Proteins ; Anti-Bacterial Agents/pharmacology ; Escherichia coli Infections/microbiology ; Bacteria ; Carbapenem-Resistant Enterobacteriaceae
    Chemical Substances carbapenemase (EC 3.5.2.6) ; Wastewater ; beta-Lactamases (EC 3.5.2.6) ; Bacterial Proteins ; Anti-Bacterial Agents
    Language English
    Publishing date 2023-11-17
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2041505-9
    ISSN 1471-2180 ; 1471-2180
    ISSN (online) 1471-2180
    ISSN 1471-2180
    DOI 10.1186/s12866-023-03108-0
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Plasmodium falciparum sexual conversion rates can be affected by artemisinin-based treatment in naturally infected malaria patients.

    Portugaliza, Harvie P / Natama, H Magloire / Guetens, Pieter / Rovira-Vallbona, Eduard / Somé, Athanase M / Millogo, Aida / Ouédraogo, D Florence / Valéa, Innocent / Sorgho, Hermann / Tinto, Halidou / van Hong, Nguyen / Sitoe, Antonio / Varo, Rosauro / Bassat, Quique / Cortés, Alfred / Rosanas-Urgell, Anna

    EBioMedicine

    2022  Volume 83, Page(s) 104198

    Abstract: Background: Artemisinins (ART) are the key component of the frontline antimalarial treatment, but their impact on Plasmodium falciparum sexual conversion rates in natural malaria infections remains unknown. This is an important knowledge gap because ... ...

    Abstract Background: Artemisinins (ART) are the key component of the frontline antimalarial treatment, but their impact on Plasmodium falciparum sexual conversion rates in natural malaria infections remains unknown. This is an important knowledge gap because sexual conversion rates determine the relative parasite investment between maintaining infection in the same human host and transmission to mosquitoes.
    Methods: The primary outcome of this study was to assess the impact of ART-based treatment on sexual conversion rates by comparing the relative transcript levels of pfap2-g and other sexual ring biomarkers (SRBs) before and after treatment. We analysed samples from previously existing cohorts in Vietnam, Burkina Faso and Mozambique (in total, n=109) collected before treatment and at 12 h intervals after treatment. As a secondary objective, we investigated factors that may influence the effect of treatment on sexual conversion rates.
    Findings: In the majority of infections from the African cohorts, but not from Vietnam, we observed increased expression of pfap2-g and other SRBs after treatment. Estimated parasite age at the time of treatment was negatively correlated with the increase in pfap2-g transcript levels, suggesting that younger parasites are less susceptible to stimulation of sexual conversion.
    Interpretation: We observed enhanced expression of SRBs after ART-based treatment in many patients, which suggests that in natural malaria infections sexual conversion rates can be altered by treatment. ART-based treatment reduces the potential of a treated individual to transmit the disease, but we hypothesise that under some circumstances this reduction may be attenuated by ART-enhanced sexual conversion.
    Funding: Spanish Agencia Estatal de Investigación (AEI), European Regional Development Fund (ERDF, European Union), Belgium Development Cooperation (DGD), Canadian University Health Network (UHN), TransGlobalHealth-Erasmus Mundus (European Union).
    MeSH term(s) Animals ; Antimalarials/therapeutic use ; Artemisinins/pharmacology ; Artemisinins/therapeutic use ; Canada ; Humans ; Malaria/parasitology ; Malaria, Falciparum/drug therapy ; Malaria, Falciparum/epidemiology ; Plasmodium falciparum
    Chemical Substances Antimalarials ; Artemisinins ; artemisinin (9RMU91N5K2)
    Language English
    Publishing date 2022-08-09
    Publishing country Netherlands
    Document type Journal Article
    ZDB-ID 2851331-9
    ISSN 2352-3964
    ISSN (online) 2352-3964
    DOI 10.1016/j.ebiom.2022.104198
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 7090: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: The public health impact and cost-effectiveness of the R21/Matrix-M malaria vaccine: a mathematical modelling study.

    Schmit, Nora / Topazian, Hillary M / Natama, H Magloire / Bellamy, Duncan / Traoré, Ousmane / Somé, M Athanase / Rouamba, Toussaint / Tahita, Marc Christian / Bonko, Massa Dit Achille / Sourabié, Aboubakary / Sorgho, Hermann / Stockdale, Lisa / Provstgaard-Morys, Samuel / Aboagye, Jeremy / Woods, Danielle / Rapi, Katerina / Datoo, Mehreen S / Lopez, Fernando Ramos / Charles, Giovanni D /
    McCain, Kelly / Ouedraogo, Jean-Bosco / Hamaluba, Mainga / Olotu, Ally / Dicko, Alassane / Tinto, Halidou / Hill, Adrian V S / Ewer, Katie J / Ghani, Azra C / Winskill, Peter

    The Lancet. Infectious diseases

    2024  Volume 24, Issue 5, Page(s) 465–475

    Abstract: Background: The R21/Matrix-M vaccine has demonstrated high efficacy against Plasmodium falciparum clinical malaria in children in sub-Saharan Africa. Using trial data, we aimed to estimate the public health impact and cost-effectiveness of vaccine ... ...

    Abstract Background: The R21/Matrix-M vaccine has demonstrated high efficacy against Plasmodium falciparum clinical malaria in children in sub-Saharan Africa. Using trial data, we aimed to estimate the public health impact and cost-effectiveness of vaccine introduction across sub-Saharan Africa.
    Methods: We fitted a semi-mechanistic model of the relationship between anti-circumsporozoite protein antibody titres and vaccine efficacy to data from 3 years of follow-up in the phase 2b trial of R21/Matrix-M in Nanoro, Burkina Faso. We validated the model by comparing predicted vaccine efficacy to that observed over 12-18 months in the phase 3 trial. Integrating this framework within a mathematical transmission model, we estimated the cases, malaria deaths, and disability-adjusted life-years (DALYs) averted and cost-effectiveness over a 15-year time horizon across a range of transmission settings in sub-Saharan Africa. Cost-effectiveness was estimated incorporating the cost of vaccine introduction (dose, consumables, and delivery) relative to existing interventions at baseline. We report estimates at a median of 20% parasite prevalence in children aged 2-10 years (PfPR
    Findings: Anti-circumsporozoite protein antibody titres were found to satisfy the criteria for a surrogate of protection for vaccine efficacy against clinical malaria. Age-based implementation of a four-dose regimen of R21/Matrix-M vaccine was estimated to avert 181 825 (range 38 815-333 491) clinical cases per 100 000 fully vaccinated children in perennial settings and 202 017 (29 868-405 702) clinical cases per 100 000 fully vaccinated children in seasonal settings. Similar estimates were obtained for seasonal or hybrid implementation. Under an assumed vaccine dose price of US$3, the incremental cost per clinical case averted was $7 (range 4-48) in perennial settings and $6 (3-63) in seasonal settings and the incremental cost per DALY averted was $34 (29-139) in perennial settings and $30 (22-172) in seasonal settings, with lower cost-effectiveness ratios in settings with higher PfPR
    Interpretation: Introduction of the R21/Matrix-M malaria vaccine could have a substantial public health benefit across sub-Saharan Africa.
    Funding: The Wellcome Trust, the Bill & Melinda Gates Foundation, the UK Medical Research Council, the European and Developing Countries Clinical Trials Partnership 2 and 3, the NIHR Oxford Biomedical Research Centre, and the Serum Institute of India, Open Philanthropy.
    MeSH term(s) Humans ; Cost-Benefit Analysis ; Malaria Vaccines/economics ; Malaria Vaccines/immunology ; Malaria Vaccines/administration & dosage ; Malaria, Falciparum/prevention & control ; Malaria, Falciparum/epidemiology ; Malaria, Falciparum/economics ; Burkina Faso/epidemiology ; Models, Theoretical ; Child, Preschool ; Public Health/economics ; Plasmodium falciparum/immunology ; Child ; Protozoan Proteins/immunology ; Antibodies, Protozoan/blood ; Vaccine Efficacy ; Infant ; Male ; Female
    Chemical Substances Malaria Vaccines ; Protozoan Proteins ; Antibodies, Protozoan ; circumsporozoite protein, Protozoan
    Language English
    Publishing date 2024-02-08
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2061641-7
    ISSN 1474-4457 ; 1473-3099
    ISSN (online) 1474-4457
    ISSN 1473-3099
    DOI 10.1016/S1473-3099(23)00816-2
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5743: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top